[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335584-105":59,"doc-detail-335584-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liu-shen-wan-inhibits-pi3kakt-and-trpv1-signaling-alleviating-bone-cancer-pain-in-rats","Liu-Shen-Wan inhibits PI3K/Akt and TRPV1 signaling alleviating bone cancer pain in rats","","Advanced-stage cancer patients often experience severe bone cancer pain driven by bone metastasis and destruction, with limited effective therapies. Liu-Shen-Wan (LSW), a widely used herbal formula for pain relief, is investigated to clarify its effects on bone cancer pain (BCP). Network pharmacology screens LSW pharmacological actions, and a Walker 256 rat model measures pain thresholds. UPLC-MS identifies active ingredients, then Bufalin’s role is tested. LSW shares 275 targets with BCP and suppresses PI3K/Akt and TRPV1 signaling via astrocytes and microglia, raising thresholds and lowering inflammatory cytokines; IGF-1 reverses benefits.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liu-shen-wan-inhibits-pi3kakt-and-trpv1-signaling-alleviating-bone-cancer-pain-in-rats/335584/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liu-shen-wan-inhibits-pi3kakt-and-trpv1-signaling-alleviating-bone-cancer-pain-in-rats/335584.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s goal regarding Liu-Shen-Wan and bone cancer pain?","Question",{"text":112,"@type":113},"To elucidate how Liu-Shen-Wan (LSW) affects bone cancer pain (BCP) and identify key pathways involved.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were pain outcomes evaluated in the rat model?",{"text":117,"@type":113},"Pain threshold measures included paw withdrawal threshold and paw withdrawal latency in Walker 256 cell-induced BCP rats.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling mechanisms does LSW target to alleviate BCP?",{"text":121,"@type":113},"LSW alleviates BCP by inhibiting PI3K/Akt and TRPV1 signaling through astrocytes and microglia, reducing inflammatory cytokines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335584,1790196842,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","CANCER BIOLOGY & THERAPY  \n2024, VOL. 25, NO. 1, 2432098 [https://doi.org/10.1080/15384047.2024.2432098](https://doi.org/10.1080/15384047.2024.2432098)  \nRESEARCH PAPER  \nLiu-Shen-Wan inhibits PI3K/Akt and TRPV1 signaling alleviating bone cancer pain in rats  \nHui Zhanga, Jingwen Jianga, Xuewu Chena, Fengting Zhua, Fangfang Fub, Aiying Chenb, Lei Fuc, and Dan Mao d  \naDepartment of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hainan Hospital, Haikou, Hainan, China; bDepartment of Oncology, Affiliated Hainan Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Haikou, Hainan, China; cDepartment of Dermatology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hainan Hospital, Haikou, Hainan, China; dDepartment of Integrated Traditional Chinese and Western Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China  \nABSTRACT  \nPatients with advanced-stage cancers often suffer from severe pain caused by bone metastasis and destruction, for which effective treatment options are limited. Liu-Shen-Wan (LSW) is a widely recognized herbal formula utilized for pain relief. This study aims to elucidate the effects of LSW on bone cancer pain (BCP) . In this study, the pharmacology of LSW on BCP was screened by network pharmacology. A BCP model was conducted using Walker 256 cells. Paw withdrawal threshold and paw withdrawal latency were employed as measures to assess the pain threshold in rats. The pathways and cell types of LSW against BCP were explored. Next, the impact of LSW on Walker 256 cells was evaluated, and UPLC-MS was utilized to identify the active ingredients of LSW. Furthermore, the effects of the key active ingredient, Bufalin, on the BCP rats were evaluated. There were 275 shared targets between LSW and BCP, which were enriched in neural tissue ligand-receptor interaction pathway. LSW increased pain threshold and decreased inflammatory cytokines levels in BCP rats by inhibiting PI3K/Akt and transient receptor potential vanilloid 1 (TRPV1) signaling through astrocytes and microglia. LY294002 further alleviated BCP in rats, while the effects were reversed after treatment with insulin-like growth factor 1 (IGF-1) . Both LSW and its active ingredient Bufalin were shown to inhibit the viability and migration of Walker 256 cells and induce apoptosis. Bufalin appears to be the key active ingredient of LSW and exerts its pain-relieving effects by suppressing PI3K/Akt and TRPV1 signaling in BCP.  \nARTICLE HISTORY  \nReceived 26 March 2024 Revised 6 June 2024 Accepted 17 November 2024  \nKEYWORDS  \nBone cancer pain; Bufalin; Liu-Shen-Wan; PI3K/Akt; TRPV1  \n1. Introduction  \nBone cancer pain (BCP) is a common complication resulting primarily from tumor metastasis to the bone.1 Factors contributing to the development of BCP include damage to sensory nerve fibers, infiltration of nerve roots and cancer cells, and the presence of pain-causing biological agents, which lead to neurochemical reorganization and persistent cancer-related pain.2 Prolonged activation generates ongoing neural signals that induce changes in the spinal cord, contributing to the progression of BCP.3 Consequently, addressing neuropathic pain maybe a crucial initial step in managing BCP. Currently, several treatment options are available for the treatment of BCP, such as nonsteroidal anti-inflammatory drugs, opioid analgesia, external beam radiation therapy, and anesthesia techniques. 1,4 However, due to the limitations of these existing treatments, many BCP patients experience inadequate pain relief and adverse side effects. Therefore, there is an urgent need to explore innovative strategies for the treatment of BCP.  \nTraditional Chinese medicine (TCM) has a long-standing history of managing cancer pain through the use of natural pharmacological agents. A Meta-analysis from Yan et al. revealed that randomized controlled trials (RCTs) involving  \n534 patients demonstrat","cbCaisxrNWF4YXmV","https://ap.wps.com/l/cbCaisxrNWF4YXmV","pdf",4864304,15,"English","# Introduction\n## Bone cancer pain and current treatments\n## Traditional Chinese medicine and LSW rationale","[{\"question\":\"What is the study’s goal regarding Liu-Shen-Wan and bone cancer pain?\",\"answer\":\"To elucidate how Liu-Shen-Wan (LSW) affects bone cancer pain (BCP) and identify key pathways involved.\"},{\"question\":\"How were pain outcomes evaluated in the rat model?\",\"answer\":\"Pain threshold measures included paw withdrawal threshold and paw withdrawal latency in Walker 256 cell-induced BCP rats.\"},{\"question\":\"Which signaling mechanisms does LSW target to alleviate BCP?\",\"answer\":\"LSW alleviates BCP by inhibiting PI3K/Akt and TRPV1 signaling through astrocytes and microglia, reducing inflammatory cytokines.\"}]","Liu-Shen-Wan inhibits PI3K/Akt and TRPV1 signaling alleviating bone cancer pain in rats | PDF",1790011519,38]